Paula Ragan, PhD, CEO and President, X4 Pharmaceuticals, discusses positive interim data from the phase 1b clinical trial (NCT04274738) evaluating mavorixafor in combination with ibrutinib in double-mutation Waldenström’s Macroglobulinemia (WM) patients.